ACE Inhibitor or ARB Initiation in High-Risk Patients

Primary Recommendation

The Kidney Disease: Improving Global Outcomes (KDIGO) guidelines recommend initiating ACE inhibitor or ARB therapy in patients with diabetes, hypertension, and albuminuria, titrating to the highest tolerated dose despite the presence of risk factors like impaired renal function, with a 1B evidence grade indicating strong support even in high-risk populations 1

ACE inhibitors and ARBs reduce cardiovascular events and slow progression of diabetic kidney disease, benefits that persist even as kidney function declines to eGFR <30 mL/min/1.73 m², in patients with diabetes and hypertension 2
The European Society of Cardiology emphasizes that hyperkalemia associated with RAS inhibitors can often be managed through dietary potassium restriction, discontinuation of potassium-sparing agents, and use of potassium binders rather than stopping the ACE inhibitor or ARB, in patients with a history of hyperkalemia 3
Patients with diabetes and impaired renal function who don't receive RAS blockade face accelerated kidney disease progression and increased cardiovascular mortality, highlighting the importance of initiating therapy 1

Before initiation, review and discontinue potassium-elevating medications, such as NSAIDs, potassium supplements, salt substitutes, potassium-sparing diuretics, and consider reducing or stopping beta-blockers if clinically feasible, to minimize the risk of hyperkalemia 3
Optimize volume status by ensuring the patient is not volume depleted, as this increases the risk of acute kidney injury, in patients with diabetes and hypertension 4
Obtain serum creatinine, eGFR, and potassium immediately before starting therapy, to establish a baseline and monitor for potential adverse effects 1
Start with the lowest approved dose of ACE inhibitor or ARB, such as lisinopril 2.5-5 mg daily or enalapril 2.5 mg twice daily, and monitor serum creatinine and potassium within 2-4 weeks after initiation or any dose increase 1, 2, 5

Dual RAS blockade is explicitly contraindicated in patients with diabetes due to increased risk of hyperkalemia, acute kidney injury, and hypotension without additional cardiovascular benefit, according to the American Diabetes Association and the European Society of Cardiology 2, 8

Discontinue any potassium supplements, NSAIDs, or potassium-sparing diuretics, and start low-dose ACE inhibitor or ARB, choosing one and never both, in patients with diabetes and hypertension 1, 3
Recheck creatinine and potassium in 2 weeks, and implement dietary potassium restriction, consider loop diuretic, and continue ACE inhibitor/ARB if potassium is 5.1-5.5 mmol/L 1, 3
Add potassium binder, such as patiromer or sodium zirconium cyclosilicate, and continue ACE inhibitor/ARB at the same dose if potassium is 5.6-6.0 mmol/L, and reduce dose by 50% or temporarily hold, address reversible factors, and then retry if potassium is >6.0 mmol/L or creatinine rises >30% 1, 3